AstraZeneca PLC Stock Flat Friday

Dow JonesJan 4 01:01

AstraZeneca (AZN.US) has initiated a Phase III clinical trial for the PD-1/TIGIT dual antibody.

AstraZeneca (AZN.US) has launched Phase III clinical trials for its PD-1/TIGIT dual antibody.

Zhitong FinanceJan 3 21:19

Unusual Options Activity: NCLH, AZN and Others Attract Market Bets, NCLH V/OI Ratio Reaches 55.6

EST Jan 2nd Afternoon Delivery - In the last two hours of trading, 4 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options trends.

Futu NewsJan 3 02:30

AstraZeneca Announces Share Capital and Voting Rights Update

TipRanksJan 2 23:02

AstraZeneca (AZN.US) "Osimertinib" has been approved for a new indication in China.

On January 2nd, the National Medical Products Administration website showed that AstraZeneca (AZN.US)'s application for the new indication of Osimertinib has officially been approved.

Zhitong FinanceJan 2 21:16

Chinese Cancer Drug Developer Hutchmed Sharpens R&D Focus, Divests Non-Core JV For Over $600 Million

BenzingaJan 2 20:38